John Connolly has a new mission to tack on to his role at the Parker Institute: interim chief of a buzzy biotech backed by a pair of billionaires
John Connolly, the new chief scientist at the Parker Institute for Cancer Immunotherapy, has a fresh mission on his plate.
Connolly’s been tapped to take the interim CEO spot at 3T Biosciences, a buzzy Bay Area startup that’s joined the whole cell therapy 2.0 movement with the help of 2 tech billionaires who have shown a big interest in cancer drug development: Peter Thiel and Sean Parker, who lent his name and direct involvement to his eponymous nonprofit.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.